Walgreens Boots Alliance Inc

Walgreens Boots Alliance — Q4 2022 Earnings Presentation

69 slides from Walgreens Boots Alliance's earnings presentation, Oct 13, 2022

  1. Slide 1: Reimagining Local Healthcare and Wellbeing for All

    Reimagining Local Healthcare and Wellbeing for All 4Q and FY22 Results October 13, 2022 © 2022 Walgreens Boots Alliance, Inc. All rights reserved.

  2. Slide 2: Safe Harbor and Non-GAAP

    Safe Harbor and Non-GAAP Cautionary Note Regarding Forward-Looking Statements: All statements in this presentation that are not historical are forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These include, without limitat

  3. Slide 3: A year of strong execution and transformation to healthcare

    A year of strong execution and transformation to healthcare • Solid close to the year, exceeding our FY22 expectations • 4Q performance better than expected, demonstrating effective management through softening global macro conditions • Providing FY23 guidance of $4.45-$4.65 in adj. EPS vs. $5.04 in

  4. Slide 4: Strategy and Road Ahead

    Strategy and Road Ahead Roz Brewer Chief Executive Officer WBA © 2022 Walgreens Boots Alliance, Inc. All rights reserved. 4

  5. Slide 5: Four key priorities capture value across core and growth spaces

    Four key priorities capture value across core and growth spaces, while strengthening assets and capabilities for the journey • Deliver best-in-class pharmacy experience more efficiently Transform and align the core Retail • Reimagine retail experience with focus on health & wellness Pharmacy • Integ

  6. Slide 6: Broadly exceeded goals despite challenging operating conditions

    Broadly exceeded goals, demonstrating our ability to Successfully executing deliver despite challenging operating conditions our strategy Strategic KPI FY22 Goal FY22 Results U.S. Retail Pharmacy segment AOI Flat/down YOY $5.03B (up YOY) Transform and align the U.S. Pharmacy core • COVID-19 vaccinat

  7. Slide 7: Our core business is resilient in the face of historic macro challenges

    Our core business is resilient in the face of historic macro challenges Drove essential pharmacy services Administered nearly 72M COVID vaccines and over 34M PCR and antigen COVID-19 tests to date, and served communities as the largest pediatric COVID-19 vaccine provider in the pharmacy channel Succ

  8. Slide 8: U.S. Healthcare segment rapidly achieving foundational milestones

    U.S. Healthcare segment rapidly achieving foundational Successfully executing milestones our strategy Strategic KPI FY22 Goal FY22 Results U.S. Healthcare sales $3.0-$3.2B $1.8B (delayed CareCentrix close) Transform and align the U.S. Healthcare pro forma sales growth − + 75% core • VillageMD − + 80

  9. Slide 9: Focusing the portfolio to fund growth and simplify the business

    Successfully executing Focusing the portfolio to fund growth and simplify the our strategy business Strategic KPI FY22 Results and Current Events Transform and align the core Strategic healthcare investments Build our next growth Optimize the portfolio to Paused strategic review of Boots due to engi

  10. Slide 10: Evolved our operating model, hired new leaders, and invested in people

    Successfully executing Evolved our operating model, hired new leaders, and made our strategy critical investments in our people Strategic KPI FY22 Results and Current Events Transform and align the Align our operating model Expanded the Executive Committee with a core with strategic priorities great

  11. Slide 11: Introducing new U.S. leaders

    Introducing new Strong healthcare team in place U.S. leaders Kevin Ban, MD Anita Allemand, PharmD Chief Medical Officer, Chief Transformation & WBA Integration Officer, WBA Lee Cooper John Do Sashi Moodley, MD Ramita Tandon EVP & President, Chief Financial Officer, Chief Clinical Officer, Chief Clin

  12. Slide 12: We are confident in the road ahead

    Successfully managing our resilient core business We are Scaling our winning healthcare assets confident in the road ahead Investing in strategic talent and capabilities Taking strong action to simplify our portfolio © 2022 Walgreens Boots Alliance, Inc. All rights reserved. Refer to safe harbor and

  13. Slide 13: 4Q & FY22 Results

    4Q & FY22 Results James Kehoe Chief Financial Officer WBA © 2022 Walgreens Boots Alliance, Inc. All rights reserved. 13

  14. Slide 14: WBA 4Q22 Financial Highlights

    Reported Fx Constant Fx Continuing operations 4Q22 $ in millions (except EPS) B/(W) vs. 4Q21 B/(W) vs. 4Q21 Sales $32,449 (5.3)% (3.2)% WBA 4Q22 Operating Income GAAP $(822) (190.2)% Financial Adjusted $744 (39.8)% (38.2)% Highlights Net Earnings GAAP $(415) (215.9)% Adjusted $694 (31.9)% (30.2)% EP

  15. Slide 15: WBA FY22 Financial Highlights

    Reported Fx Constant Fx Continuing operations FY22 $ in millions (except EPS) B/(W) vs. FY21 B/(W) vs. FY21 Sales $132,703 + 0.1% + 1.2% WBA FY22 Operating Income GAAP $1,387 (40.8)% Financial Adjusted $5,133 + 0.3% + 1.2% Highlights Net Earnings GAAP $4,337 + 117.5% Adjusted $4,360 + 2.5% + 3.3% EP

  16. Slide 16: U.S. Retail Pharmacy Financials

    4Q22 B/(W) vs. 4Q21 FY22 B/(W) vs. FY21 $ in millions Sales $26,683 (7.2)% $109,078 (2.6)% Adj. gross profit $5,413 (13.2)% $23,827 + 0.3% Adj. SG&A % of sales 17.9% (0.1)%p 17.8% (0.6)%p U.S. Retail Adj. operating income $786 (36.1)% $5,029 + 0.2% Pharmacy Adj. operating margin1 2.4% (1.5)%p 4.0% +

  17. Slide 17: U.S. Pharmacy

    4Q22 4Q22 FY22 FY22 4Q22 vs. 4Q21 | FY22 vs. FY21 Total Comparable Total Comparable Pharmacy sales (8.8)% + 3.0% (5.3)% + 4.7% Prescriptions (4.4)% (3.5)% + 0.5% + 1.3% Prescriptions ex. (1.1)% (0.1)% + 0.6% + 1.4% Immunizations U.S. Pharmacy • 4Q comp scripts (3.5)%; excluding immunizations, comp s

  18. Slide 18: U.S. Retail

    4Q22 FY22 4Q22 vs. 4Q21 | FY22 vs. FY21 Total retail sales (2.4)% + 5.6% Comparable retail sales (1.9)% + 6.1% • 4Q comp retail sales (1.9)%, lapping strong sales of COVID-19 related items and the U.S. Retail planned decline in tobacco − Comp excluding tobacco (1.1)% − Three-year stack excluding tob

  19. Slide 19: International Financials

    Constant Fx Constant Fx Continuing operations 4Q22 FY22 $ in millions B/(W) vs. 4Q21 B/(W) vs. FY21 Sales $5,144 + 6.7% $21,830 + 13.3% Adj. gross profit $1,110 + 5.4% $4,618 + 12.2% Adj. SG&A % of sales 18.4% + 0.9%p 17.8% + 1.3%p International Adj. operating income $163 + 31.3% $726 + 65.5% Financ

  20. Slide 20: Boots UK Financials

    4Q22 FY22 4Q22 vs. 4Q21 | FY22 vs. FY21 (constant Fx) Pharmacy comp. sales (6.9)% + 1.1% Retail comp. sales + 15.2% + 19.2% Boots UK • Pharmacy comp sales lapping strong demand for COVID-19 services in 4Q21 Financials • Boots growing retail market share, notably in Personal Care and Health and Welln

  21. Slide 21: U.S. Healthcare Financials

    4Q22 B/(W) vs. 4Q21 FY22 B/(W) vs. FY21 $ in millions Sales $622 + $622 $1,795 + $1,795 Adj. gross profit $(9) $(9) $6 + $6 Adj. SG&A $(143) $(117) $(376) $(319) U.S. Healthcare Adj. operating loss $(151) $(126) $(370) $(313) Financials • 4Q U.S. Healthcare pro forma sales growth +34% − VillageMD pr

  22. Slide 22: Cash Flow

    B/(W) FY22 $ in millions vs. FY21 Operating cash flow $3,899 $(1,656) Cash capital expenditure $(1,734) $(355) Free cash flow $2,165 $(2,011) Cash Flow • Cash generation of $3.9B in operating cash flow and $2.2B of free cash flow • Year-over-year operating cash flow adversely impacted by: − Unwind o

  23. Slide 23: Guidance

    Guidance James Kehoe Chief Financial Officer WBA © 2022 Walgreens Boots Alliance, Inc. All rights reserved. 23

  24. Slide 24: Confident in long-term growth algorithm; strong FY23 core growth

    Confident in long-term growth algorithm; strong FY23 core growth more than offset by lower levels of vaccinations & testing • FY23 adj. EPS guidance of $4.45-$4.65 vs. FY22 adj. EPS of $5.04 • Strong core business driving 8-10% of EPS growth; offset by: − Lapping strong COVID-19 execution: 15-17% he

  25. Slide 25: WBA FY23 Outlook

    CFx % YOY WBA FY23 CFx % YOY Change ex. COVID-19 Sales $130.5 - $134.0B 0% - +3% +2% - +4% Adj. Op. Income $4.7 - $4.9B (7)% - (4)% +13% - +16% Adj. EPS $4.45 - $4.65 (10)% - (6)% +8% - +10% WBA FY23 Key Considerations: Outlook • COVID-19 EPS headwind of 15-17% ($0.75-$0.85) • Healthy core business

  26. Slide 26: U.S. Retail Pharmacy FY23 Outlook

    % YOY ex. U.S. Retail Pharmacy FY23 % YOY Change COVID-19 U.S. Retail Sales $105.5 - $107.5B (3)% - (1)% (1)% - +1% Pharmacy Adj. Op. Income $4.5 - $4.6B (10)% - (9)% +10% - +11% Strong core Adj. Op. Margin1 ~3.7% at Midpoint (30) bps +45 bps AOI growth Key Considerations: partly • Sales down LSD du

  27. Slide 27: International FY23 Outlook

    International FY23 % YOY Change CFx % YOY Sales $20.4 - $20.9B (7)% - (4)% +5% - +7% International Adj. Op. Income $830 - $870M +14% - +20% +26% - +32% Continued Adj. Op. Margin ~4.0% at Midpoint +70 bps +65 bps post- Key Considerations: pandemic • Fx expected to be a 11-12% headwind to sales and AO

  28. Slide 28: U.S. Healthcare FY23 Outlook

    U.S. Healthcare FY23 % YOY Change Sales $4.9 - $5.3B +175% - +195% Adj. Op. Income $(350) - $(330)M +5% - +11% U.S. Healthcare Adj. EBITDA $(240) - $(220)M +23% - +29% Accelerating to Key Considerations: positive adj. • Sales of ~$5B including full year of contributions from recent acquisitions EBIT

  29. Slide 29: U.S. Healthcare segment scaling to $5B in sales

    U.S. Healthcare segment scaling to $5B in sales, with 45-55% pro forma growth $ millions FY22 FY23 % YOY Change Pro Forma % Sales $1,795 $4,900 - $5,300 +175% - +195% +45% - +55% VillageMD $1,509 $2,830 - $3,070 +85% - +105% +50% - +60% CareCentrix - $1,520 - $1,620 - +20% - +30% Shields $286 $430 -

  30. Slide 30: FY23 corporate assumptions

    FY23 corporate assumptions $ millions FY22 FY23 Comments • Expected at 20%+ in FY24 and beyond, due to Adj. Tax Rate 15.5% ~16% legislative changes Interest Expense $(395) $(500) - $(490) • Reflects higher interest rates • Anti-dilutive share purchases only Share Repurchases $- $- • Flexibility for

  31. Slide 31: Confident in the long-term growth algorithm

    Confident in the long-term growth algorithm Adj. EPS Outlook Low-Teens Growth FY25 MSD-HSD Growth $5.04 $4.45-$4.65 (10)-(6)% YOY CFx FY22 FY24 Includes Increasing Tax FY23 Rate and Modest Ex COVID-19 8-10% CFx Growth COVID-19 Headwind Tailwind Ex COVID-19 • Revenue growth: Balanced across U.S. Reta

  32. Slide 32: Capital allocation priorities underpin financial projections

    Capital allocation priorities underpin financial projections •1 Investment in the Core •2 Strategic M&A and Portfolio Simplification • Disciplined, returns-based investment in • Value-accretive M&A aligned to strategy the core business • Portfolio simplification to unlock value •3 Strong Balance She

  33. Slide 33: Raising U.S. Healthcare sales outlook

    U.S. Healthcare Segment Sales Outlook VillageMD Shields CareCentrix Walgreens Health $11.0 - $12.0B Raising U.S. Prior Goal: Healthcare $7.0 - $8.0B $9 - $10B sales outlook $4.9 - $5.3B to $11-12B, $1.8B from $9-10B FY22 FY23 Goal FY24 Goal FY25 Goal +75% ~+50% Pro Forma 3-Year CAGR Growth © 2022 Wa

  34. Slide 34: Clear path to profitability

    U.S. Healthcare Segment Adj. EBITDA and Margin Outlook FY22 FY23 FY24 FY25 Long-Term $ in millions Profitability Drivers • Moving past FY22 peak investment period Clear path to $500-$700 • Achieving scale across the U.S. Healthcare portfolio $125-$225 profitability • Maturing VMD clinic profile • Sh

  35. Slide 35: FY23 core growth partly offsets COVID-19 impact

    FY23 core growth partly offsets COVID-19 impact; execution of healthcare strategy leads to confidence in long-term growth Positive Underlying • Resilient core U.S. business and continued International recovery Momentum Partly • Lapping strong COVID-19 execution Offsets COVID-19 • Expecting 8-10% con

  36. Slide 36: U.S. Healthcare

    U.S. Healthcare John Driscoll EVP & President U.S. Healthcare Segment © 2022 Walgreens Boots Alliance, Inc. All rights reserved. 36

  37. Slide 37: Introducing our new leader for U.S. Healthcare

    Introducing our new leader for U.S. Healthcare Excited to transform the healthcare system 25+ years in healthcare • CEO, CareCentrix • Former President, Castlight Health • Led new markets at Medco ($70B PBM) • Founded Surescripts ePrescribing Network Health • B.A. and MBA from Harvard University, MP

  38. Slide 38: U.S. Healthcare expands WBA into larger, faster-growing profit pools

    U.S. Healthcare expands WBA into larger, faster-growing profit pools 2025 EBITDA Profit Pools1 $135B ($ billions) 13.5 Provider Enablement / MSO Strong foundation > 10% growth rate 9.5 Population Health in retail and specialty pharmacy 5-10% growth rate < 0% growth rate services 20.8 Home Health Hea

  39. Slide 39: Consumer-centric, tech-enabled care model across the care continuum

    Our consumer-centric, tech-enabled care model will engage across the care continuum and drive synergies across the portfolio Wellness & Prevention Pre-acute Primary care Specialty care Post-acute Retail Pharmacy Health Corners Retail pharmacy services, Pharmacist-led chronic Value-based primary care

  40. Slide 40: Scaling industry-leading healthcare assets to reimagine care delivery

    Scaling industry-leading healthcare assets to reimagine care delivery Leading capabilities Integrated Healthcare offering Best-in-class value-based primary care U.S. Healthcare segment >26M Next generation of specialty pharmacy Lives under management across portfolio >12K Outcomes-driven post-acute

  41. Slide 41: Deep community relationships

    Deep community Retail Pharmacy Walgreens relationships offerings health services Pharmacy & Healthcare Services 96M 48M+ 2.3M+ Overview: Annual pharmacy Vaccines administered Total lives covered Engaging consumers in patients1 (COVID-19, flu, and non-flu) through health plan partners localized healt

  42. Slide 42: VillageMD: Scalable model, accepts all patients, superior outcomes

    Scalable model Accepts all patients Superior outcomes 342 1.6M+ $2,400 clinics Overview: Leading player in Total patients Annual savings Provider-led, value-based value-based primary care1 per MA patient2 care organization focused on delivering the best health outcomes to all 22 430K+ 88 patient pop

  43. Slide 43: Best-in-class at addressing all pain points at scale

    Best-in-class at addressing all pain points at scale Risk-Based Tech-Enabled, Provider Aggregators / Primary Care Providers Fee-for-Service Providers Services Organizations Retail Health Providers e.g. Oak Street Health, Cano Health e.g. One Medical e.g. Agilon Health e.g. Walmart Health Patient div

  44. Slide 44: Shields: hospital-owned specialty pharmacy programs

    Unique service model Integrated pharmacy Capturing more value for specialty pharmacy and clinical care team for health systems 75 100K+ $3.1B Health System Active Patients Fulfillment Partners on Care Model Sales Overview: High-touch service model Superior identification of Access to payor networks

  45. Slide 45: Driving superior results for patients, providers, and payors

    Driving superior results for patients, providers, and payors Market Market Averages Averages to Average Time to Patients Co-Pay ~$100 ~$8 Therapy 21 days 48 hrs to Medication Annual Patient Physicians Adherence 65% 92% Interactions <10 30+ to Commercial Specialty Health Systems Payor Access <10% 90%

  46. Slide 46: CareCentrix: post-acute and home services platform

    National Best-in-class Superior care scale & reach outcomes experience Overview: 19M 18-25% >90% Provider Independent, payor- Contracted Lives Reduction Satisfaction agnostic post-acute and home services platform to Value-based contracts Lower readmissions rate Positive experience for accelerate val

  47. Slide 47: Home benefit management portfolio

    Broadest value-based platform for coordinated home services Traditional benefits Traditional post-acute Value-based home Value-based home health management management health assessments benefits management e.g. EviCore Healthcare e.g. NaviHealth e.g. Signify Health e.g. MyNexus Independent National

  48. Slide 48: Unbeatable combination of physical and digital care delivery

    Unbeatable combination of physical and digital care delivery Wellness & Prevention Pre-acute Primary care Specialty care Post-acute Retail Pharmacy Health Corners Local, trusted healthcare across the continuum Consumer engagement through an omni-channel and personalized experience Integrated health

  49. Slide 49: Summary

    Summary Roz Brewer Chief Executive Officer WBA © 2022 Walgreens Boots Alliance, Inc. All rights reserved. 49

  50. Slide 50: A year of strong execution and transformation to healthcare

    A year of strong execution and transformation to healthcare • Executing well in a challenging environment • Accelerating growth and profitability in our U.S. Healthcare business, with raised targets for the segment • Making significant progress on talent and capabilities • Rapidly simplifying the po

  51. Slide 51: Q&A

    Q&A © 2022 Walgreens Boots Alliance, Inc. All rights reserved. 51

  52. Slide 52: Thank You

    Thank You © 2022 Walgreens Boots Alliance, Inc. All rights reserved. 52

  53. Slide 53: Endnotes

    Endnotes • Please see appendix for reconciliations of non-GAAP financial measures and related disclosures • The Company presents certain information related to current period operating results in “constant currency,” which is a non-GAAP financial measure. These amounts are calculated by translating

  54. Slide 54: Appendix

    Appendix The information on the following pages provides reconciliations of the supplemental non-GAAP financial measures, as defined under SEC rules, presented in this presentation and discussed on the related conference call to the most directly comparable financial measures calculated and presente

  55. Slide 55: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) NET EARNINGS Three months ended August 31, Change vs. 4Q21 Twelve months ended August 31, Change vs. FY21 2022 2021 Amount Percent 2022 2021 Amount Percent

  56. Slide 56: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) NET EARNINGS Three months ended August 31, Change vs. 4Q21 Twelve months ended August 31, Change vs. FY21 2022 2021 Amount Percent 2022 2021 Amount Percent

  57. Slide 57: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) NET EARNINGS Three months ended August 31, Change vs. 4Q21 Twelve months ended August 31, Change vs. FY21 2022 2021 Amount Percent 2022 2021 Amount Percent

  58. Slide 58: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) DILUTED NET EARNINGS (LOSS) PER SHARE Three months ended August 31, Change vs. 4Q21 Twelve months ended August 31, Change vs. FY21 2022 2021 Amount Percent

  59. Slide 59: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) U.S. Healthcare - Adjusted EBITDA Twelve months ended August 31, 2022 18 Operating loss (GAAP) $ (829) Acquisition-related amortization2 392 5 Acquisition-

  60. Slide 60: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) 1 Adjustments to equity earnings (loss) in AmerisourceBergen consist of the Company’s proportionate share of non-GAAP adjustments reported by AmerisourceBergen consisten

  61. Slide 61: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) 15 Adjustments to post tax earnings from other equity method investments consist of the proportionate share of certain equity method investees’ non-cash items or unusual

  62. Slide 62: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) Three months ended August 31, 2022 Walgreens Boots U.S. Retail Pharmacy 1 International U.S. Healthcare Corporate and Other Alliance, Inc. Sales $ 26,683 $

  63. Slide 63: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) Three months ended August 31, 2021 Walgreens Boots U.S. Retail Pharmacy 1 International U.S. Healthcare 3 Corporate and Other Alliance, Inc. Sales $ 28,755

  64. Slide 64: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) Twelve months ended August 31, 2022 Walgreens Boots U.S. Retail Pharmacy 1 International U.S. Healthcare Corporate and Other Alliance, Inc. Sales $ 109,078

  65. Slide 65: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) Twelve months ended August 31, 2021 Walgreens Boots U.S. Retail Pharmacy 1 International U.S. Healthcare 3 Corporate and Other Alliance, Inc. Sales $ 112,0

  66. Slide 66: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) 1 Operating income (loss) for U.S. Retail Pharmacy segment includes equity earnings (loss) in AmerisourceBergen. As a result of the two month reporting lag

  67. Slide 67: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) EQUITY EARNINGS (LOSS) IN AMERISOURCEBERGEN Three months ended August 31, Twelve months ended August 31, 2022 2021 2022 2021 Equity earnings (loss) in Amer

  68. Slide 68: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) ADJUSTED EFFECTIVE TAX RATE Three months ended August 31, 2022 Three months ended August 31, 2021 Earnings (loss) Income tax Earnings before Income tax bef

  69. Slide 69: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) FREE CASH FLOW Three months ended August 31, Twelve months ended August 31, 2022 2021 2022 2021 Net cash provided by operating activities (GAAP) $ 85 $ 1,2

Walgreens Boots Alliance — Q4 2022 Earnings Presentation on 6ix